Phys Vivas · dermatological
Pyoderma Gangrenosum AND Neutrophilic Dermatoses — Viva Defence
DCE viva defence for Pyoderma Gangrenosum AND Neutrophilic Dermatoses.
On this page & tools
Target exams
Pyoderma Gangrenosum AND Neutrophilic Dermatoses Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Pyoderma Gangrenosum AND Neutrophilic Dermatoses. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Balan K, Elston DM IL-1-targeted therapy in dermatologic conditions J Am Acad Dermatol, 2026.PMID 42264383
- [2]Kerniss H, Olbrich H, Curman P, Ständer S, et al. Pyoderma gangrenosum is associated with excess incident major atherothrombotic events Atherosclerosis, 2026.PMID 42263577
- [3]Rahman S, Akuffo-Addo E, Geng R, Bestavros S, et al. Genital Pyoderma Gangrenosum: A Systematic Review of Reported Cases and Treatment Outcomes J Cutan Med Surg, 2026.PMID 42109214
- [4]Haddadin OM, Jacobson ME, Becker SL, Chen D, et al. Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus Br J Dermatol, 2026.PMID 41784109
- [5]Yamamoto T, Yamasaki K, Yamanaka K, Komine M, et al. Clinical guidance of pyoderma gangrenosum 2022 J Dermatol, 2023.PMID 37311717
- [6]Maverakis E, Ma C, Shinkai K, Fiorentino D, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts JAMA Dermatol, 2018.PMID 29450466
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922